Once-daily maraviroc in combination with ritonavir-boosted atazanavir in treatment-naive patients infected with CCR5-tropic HIV-1 (study A4001078): 96-week results

被引：0
|
作者：
Mills, A. [1 ]
Mildvan, D. [2 ]
Podzamczer, D. [3 ]
Faetkenheuer, G. [4 ]
Leal, M. [5 ]
Than, S. [6 ]
Valluri, S. R. [9 ]
Craig, C. [10 ]
Vourvahis, M. [9 ]
Heera, J. [6 ]
Valdez, H. [9 ]
Brown, T. [7 ]
Rinehart, A. [8 ]
Portsmouth, S. [9 ]
机构：
[1] Anthony Mills MD Inc, Los Angeles, CA USA
[2] Beth Israel Deaconess Med Ctr, Div Infect Dis, New York, NY 10003 USA
[3] Hosp Univ Bellvitge, HIV Unit, Infect Dis Serv, Barcelona, Spain
[4] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[5] Virgen del Rocio Univ Hosp, Infect Dis Serv, Seville, Spain
[6] Pfizer Inc, Groton, CT 06340 USA
[7] Johns Hopkins Univ, Div Endocrinol & Metab, Baltimore, MD USA
[8] ViiV Healthcare, Res Triangle Pk, NC USA
[9] Pfizer Inc, New York, NY USA
[10] Pfizer Inc, Sandwich, Kent, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：52 / 53
页数：2
相关论文
共 50 条
  • [1] Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
    Mills, Anthony M.
    Nelson, Mark
    Jayaweera, Dushyantha
    Ruxrungtham, Kiat
    Cassetti, Isabel
    Girard, Pierre-Marie
    Workman, Cassy
    Dierynck, Inge
    Sekar, Vanitha
    Abeele, Carline Vanden
    Lavreys, Ludo
    AIDS, 2009, 23 (13) : 1679 - 1688
  • [2] Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients
    Pulido, Ildefonso
    Genebat, Miguel
    Alvarez-Rios, Ana I.
    De Pablo-Bernal, Rebeca S.
    Rafii-El-Idrissi Benhnia, Mohammed
    Pacheco, Yolanda M.
    Ruiz-Mateos, Ezequiel
    Leal, Manuel
    VIRAL IMMUNOLOGY, 2016, 29 (08) : 471 - 477
  • [3] Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study
    Elion, Richard
    deJesus, Edwin
    Sension, Michael
    Berger, Daniel
    Towner, William
    Richmond, Gary
    Clair, Marty St.
    Yau, Linda
    Ha, Belinda
    HIV CLINICAL TRIALS, 2008, 9 (03): : 152 - 163
  • [4] Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study
    Molina, Jean-Michel
    Andrade-Villanueva, Jaime
    Echevarria, Juan
    Chetchotisakd, Ploenchan
    Corral, Jorge
    David, Neal
    Moyle, Graeme
    Mancini, Marco
    Percival, Lisa
    Yang, Rong
    Wirtz, Victoria
    Lataillade, Max
    Absalon, Judith
    McGrath, Donnie
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (03) : 323 - 332
  • [5] Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naive patients: a pilot study
    Nishijima, Takeshi
    Tsukada, Kunihisa
    Teruya, Katsuji
    Gatanaga, Hiroyuki
    Kikuchi, Yoshimi
    Oka, Shinichi
    AIDS, 2012, 26 (05) : 649 - 651
  • [6] Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO
    Molina, Jean-Michel
    Clotet, Bonaventura
    van Lunzen, Jan
    Lazzarin, Adriano
    Cavassini, Matthias
    Henry, Keith
    Kulagin, Valeriv
    Givens, Naomi
    Brennan, Clare
    de Oliveira, Carlos Fernando
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 6 - 7
  • [7] Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS
    Arathoon, E.
    Schneider, S.
    Baraldi, E.
    Lim, P. L.
    Opravil, M.
    Van De Casteele, T.
    Lavreys, L.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2013, 24 (01) : 12 - 17
  • [8] Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naive HIV-1-infected ARTEMIS patients at week 96
    Baraldi, E.
    Morales-Ramirez, J.
    Schneider, S.
    Stoehr, A.
    Orani, A.
    Van De Casteele, T.
    Lavreys, L.
    Hill, A.
    ANTIVIRAL THERAPY, 2009, 14 (07) : A55 - A56
  • [9] Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/Ritonavir in HIV-1-Infected, Treatment-Naive ARTEMIS Patients at Week 96
    Fourie, Jan
    Flamm, Jason
    Rodriguez-French, Amalia
    Kilby, Don
    Domingo, Pere
    Lazzarin, Adriano
    Ballesteros, Juan
    Sosa, Nestor
    Van De Casteele, Tom
    DeMasi, Ralph
    Spinosa-Guzman, Sabrina
    Layreys, Ludo
    HIV CLINICAL TRIALS, 2011, 12 (06): : 313 - 322
  • [10] Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    Ortiz, Roberto
    DeJesus, Edwin
    Khanlou, Homayoon
    Voronin, Evgeniy
    van Lunzen, Jan
    Andrade-Villanueva, Jaime
    Fourie, Jan
    De Meyer, Sandra
    De Pauw, Martine
    Lefebvre, Eric
    Vangeneugden, Tony
    Spinosa-Guzman, Sabrina
    AIDS, 2008, 22 (12) : 1389 - 1397
12345